230 related articles for article (PubMed ID: 24549827)
1. Mechanism - based translational pharmacokinetic - pharmacodynamic model to predict intraocular pressure lowering effect of drugs in patients with glaucoma or ocular hypertension.
Durairaj C; Shen J; Cherukury M
Pharm Res; 2014 Aug; 31(8):2095-106. PubMed ID: 24549827
[TBL] [Abstract][Full Text] [Related]
2. Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. ALPHAGAN/XALATAN Study Group.
Simmons ST; Samuelson TW
Clin Ther; 2000 Apr; 22(4):388-99. PubMed ID: 10823361
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial.
DuBiner HB; Mroz M; Shapiro AM; Dirks MS;
Clin Ther; 2001 Dec; 23(12):1969-83. PubMed ID: 11813932
[TBL] [Abstract][Full Text] [Related]
4. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.
Katz LJ; Rauchman SH; Cottingham AJ; Simmons ST; Williams JM; Schiffman RM; Hollander DA
Curr Med Res Opin; 2012 May; 28(5):781-8. PubMed ID: 22458918
[TBL] [Abstract][Full Text] [Related]
5. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering.
Simmons ST; Earl ML;
Ophthalmology; 2002 Feb; 109(2):307-14; discussion 314-5. PubMed ID: 11825814
[TBL] [Abstract][Full Text] [Related]
6. Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension.
Mundorf T; Noecker RJ; Earl M
Adv Ther; 2007; 24(2):302-9. PubMed ID: 17565920
[TBL] [Abstract][Full Text] [Related]
7. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models.
Krauss AH; Impagnatiello F; Toris CB; Gale DC; Prasanna G; Borghi V; Chiroli V; Chong WK; Carreiro ST; Ongini E
Exp Eye Res; 2011 Sep; 93(3):250-5. PubMed ID: 21396362
[TBL] [Abstract][Full Text] [Related]
8. Latanoprost : an update of its use in glaucoma and ocular hypertension.
Perry CM; McGavin JK; Culy CR; Ibbotson T
Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
[TBL] [Abstract][Full Text] [Related]
9. Latanoprost or brimonidine as treatment for elevated intraocular pressure: multicenter trial in the United States.
Camras CB; Sheu WP;
J Glaucoma; 2005 Apr; 14(2):161-7. PubMed ID: 15741820
[TBL] [Abstract][Full Text] [Related]
10. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
Orzalesi N; Rossetti L; Bottoli A; Fumagalli E; Fogagnolo P
Arch Ophthalmol; 2003 Apr; 121(4):453-7. PubMed ID: 12695241
[TBL] [Abstract][Full Text] [Related]
11. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study.
Kampik A; Arias-Puente A; O'Brart DP; Vuori ML;
J Glaucoma; 2002 Apr; 11(2):90-6. PubMed ID: 11912355
[TBL] [Abstract][Full Text] [Related]
12. Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients.
Liu CJ; Ko YC; Cheng CY; Chiu AW; Chou JC; Hsu WM; Liu JH
Ophthalmology; 2002 Dec; 109(12):2241-7. PubMed ID: 12466165
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey.
Savinainen A; Prusakiewicz JJ; Oswald J; Spencer E; Lou Z; Cohen ML; Rashidzadeh H; Josiah S
Exp Eye Res; 2019 Dec; 189():107836. PubMed ID: 31626797
[TBL] [Abstract][Full Text] [Related]
14. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension.
Day DG; Hollander DA
Curr Med Res Opin; 2008 May; 24(5):1435-42. PubMed ID: 18402717
[TBL] [Abstract][Full Text] [Related]
15. Microbead-induced ocular hypertensive mouse model for screening and testing of aqueous production suppressants for glaucoma.
Yang Q; Cho KS; Chen H; Yu D; Wang WH; Luo G; Pang IH; Guo W; Chen DF
Invest Ophthalmol Vis Sci; 2012 Jun; 53(7):3733-41. PubMed ID: 22599582
[TBL] [Abstract][Full Text] [Related]
16. Human experience and efficacy of omidenepag isopropyl (Eybelis®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug.
Sharif NA
Curr Opin Pharmacol; 2024 Feb; 74():102426. PubMed ID: 38168596
[TBL] [Abstract][Full Text] [Related]
17. Four years later: a clinical update on latanoprost.
Ravinet E; Mermoud A; Brignoli R
Eur J Ophthalmol; 2003 Mar; 13(2):162-75. PubMed ID: 12696636
[TBL] [Abstract][Full Text] [Related]
18. Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination.
Fuwa M; Ueda K; Akaishi T; Yamashita N; Kirihara T; Shimazaki A; Mano H; Kawazu K
PLoS One; 2016; 11(7):e0158797. PubMed ID: 27383260
[TBL] [Abstract][Full Text] [Related]
19. A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma.
Borghi V; Bastia E; Guzzetta M; Chiroli V; Toris CB; Batugo MR; Carreiro ST; Chong WK; Gale DC; Kucera DJ; Jia L; Prasanna G; Ongini E; Krauss AH; Impagnatiello F
J Ocul Pharmacol Ther; 2010 Apr; 26(2):125-32. PubMed ID: 20415621
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma.
Fung AT; Reid SE; Jones MP; Healey PR; McCluskey PJ; Craig JC
Br J Ophthalmol; 2007 Jan; 91(1):62-8. PubMed ID: 16956912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
